Chapter 11 of 25
- I: selected uterus-confined patterns, plus tightly defined IA3 exception
- II: cervical stroma, substantial LVSI or aggressive invasive biology
- III: regional tissues, pelvic peritoneum or regional nodes
- IV: organ mucosa, extrapelvic peritoneum or distant spread
What you will learn
- Understand the main FIGO 2023 categories and their important substages.
- Recognize when molecular findings modify early-stage labels.
- Compare older reports without assuming that the cancer has worsened.
Why the version matters
Endometrial cancer is usually surgically staged using the operation and pathology findings. Before surgery, examination and imaging provide an estimate. If surgery is unsuitable, the team documents the best available clinical assessment and its limitations. Older studies commonly used FIGO 2009 or other earlier systems, which are not directly interchangeable with FIGO 2023.
In the table below, nonaggressive histology generally means low-grade endometrioid carcinoma. Aggressive histology includes grade-3 endometrioid, serous, clear cell, carcinosarcoma, undifferentiated and certain other uncommon types. Molecular results can further modify early-stage classification. The full report should name the staging version.
Stage-by-stage framework
| FIGO 2023 stage | Simplified definition before relevant molecular modification |
|---|---|
| IA1 | Nonaggressive cancer confined to a polyp or endometrium |
| IA2 | Nonaggressive cancer invading less than half the myometrium, with no or focal LVSI |
| IA3 | Low-grade endometrioid cancer involving uterus and one ovary, meeting all specified favourable criteria |
| IB | Nonaggressive cancer invading half or more of the myometrium, with no or focal LVSI |
| IC | Aggressive histology confined to a polyp or endometrium, without myometrial invasion |
| IIA | Nonaggressive histology invading cervical stroma |
| IIB | Nonaggressive histology with substantial LVSI |
| IIC | Aggressive histology with any myometrial invasion |
| IIIA1 | Ovarian or tubal spread, except cases meeting IA3 criteria |
| IIIA2 | Involvement of uterine subserosa or spread through serosa |
| IIIB1 | Vaginal or parametrial spread |
| IIIB2 | Pelvic peritoneal metastasis |
| IIIC1 | Pelvic lymph-node metastasis |
| IIIC2 | Para-aortic nodes up to renal vessels, with or without pelvic nodes |
| IVA | Bladder or bowel mucosal invasion |
| IVB | Peritoneal spread beyond the pelvis |
| IVC | Distant spread, including nodes above the renal vessels |
IA3 requires less than half muscle invasion, no substantial LVSI, no additional metastases and unilateral ovarian involvement without capsule breach. It should not be used for all cancers involving both uterus and ovary. Cervical gland involvement alone is not cervical stromal invasion. FIGO uses at least five involved vessels for substantial LVSI; the pathologist makes this assessment.
For IIIC1 and IIIC2, suffix i denotes micrometastasis and ii denotes macrometastasis. Isolated tumour cells are recorded but do not alone upstage disease. Positive peritoneal washings are reported separately and do not by themselves determine the FIGO stage.
Molecular modifications
A qualifying pathogenic POLE mutation in disease confined to the uterus, with or without cervical extension, can produce the designation IAm-POLEmut. p53-abnormal disease with myometrial invasion, confined to the uterus with or without cervical extension, is designated IICm-p53abn. MMRd and NSMP are recorded but do not change the early-stage category in this way.
Molecular findings do not downstage anatomical stage III or IV. A favourable POLE result must not erase known nodal or distant spread. Multiple-classifier tumours require integrated pathological interpretation before a molecular stage is assigned.
Examples and questions
Low-grade endometrioid cancer with superficial muscle invasion and focal LVSI may be IA2. The same nonaggressive histology with substantial LVSI can be IIB despite no cervical spread. Serous carcinoma without muscle invasion may be IC; with invasion it can fall into IIC or the relevant molecular category if otherwise confined. These examples are teaching illustrations, not a substitute for reviewing the complete specimen.
Ask: Which FIGO version is used? Is the stage final? What molecular information changed the label? Does a different label reflect a new classification rather than newly discovered spread? Stage informs care, but the recurrence-risk group and the patient's circumstances determine the final recommendation.
Related chapters
- How Doctors Choose Treatment
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- Berek et al. FIGO staging of endometrial cancer, 2023
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- NCI: Endometrial Cancer Treatment PDQ
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy